Table. 3.

Severity, complications, and management of COVID-19 infections

Variable All (n=87) Survivor (n=67) Non-survivor (n=20) P-value
Disease severity at time of presentation
Asymptomatic 13 (15) 12 (18) 1 (5) 0.155
Mild 21 (24) 21 (31) 0 0.004
Moderate 39 (45) 26 (39) 13 (65) 0.039
Severe 10 (11) 7 (10) 3 (15) 0.575
Critical 4 (5) 1 (1) 3 (15) 0.011
Progression to more severe COVID-19 infection 18 (21) 7 (10) 11 (55) 0.005
Admission to hospital 79 (91) 60 (89) 19 (95) 0.459
Admission to the ICU 9 (10) 0 9 (45) <0.001
Oxygen supplementationa) 21/62 (34) 12/48 (25) 9/14 (64) 0.025
AKI 25 (29) 11 (16) 14 (70) <0.001
Multi-organ failure 13 (15) 0 13 (65) 0.005
Respiratory failure requiring ventilationa) 9/62 (14) 1/48 (2) 8/14 (57) <0.001
Renal replacement therapya) 9/62 (14) 0/48 (0) 9/14 (64) <0.001
Renal allograft rejection 10 (11) 1 (1) 9 (45) <0.001
Cardiac injury 7 (8) 3 (4) 4 (20) 0.025
Shock 7 (8) 0 7 (35) 0.005
Arrhythmias 5 (6) 2 (3) 3 (15) 0.043
Cytopenias 3 (3) 0 3 (15) 0.001
Liver injury 3 (3) 2 (3) 1 (5) 0.665
Thrombosis 1 (1) 0 1 (5) 0.066
Coagulopathy 1 (1) 0 1 (5) 0.066
Secondary infections 4 (5) 2 (3) 2 (10) 0.189
Increased doses of corticosteroidsa) 41/62 (66) 30/47 (64) 11/15 (73) 0.534
Anticoagulationa) 38/62 (61) 24/47 (51) 14/15 (93) 0.003
Antiviralsa) 31/62 (50) 18/47 (38) 13/15 (87) 0.001
Antibioticsa) 28/62 (45) 18/47 (38) 10/15 (67) 0.025
Reduction in immunosuppressiona) 27/62 (43) 21/47 (45) 6/15 (40) 0.750
Reduction or discontinuation of calcineurin inhibitors 16/62 (26) 11/47 (23) 5/15 (33) 0.243
Reduction or discontinuation of anti-metabolite 29/62 (47) 23/47 (49) 6/15 (40) 0.444
Hydroxychloroquinea) 12/62 (19) 8/47 (17) 4/15 (27) 0.410
Azithromycina) 10/62 (16) 6/47 (13) 4/15 (27) 0.150

Values are presented as number (%).

COVID-19, coronavirus disease 2019; ICU, intensive care unit; AKI, acute kidney injury.

a)Data for 25 patients not available.

Korean J Transplant 2021;35:218~229 https://doi.org/10.4285/kjt.21.0024
© Clin Transplant Res